Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Sernova (OTC:SEOVF) announced final closing of previously disclosed financings after shareholder approval on April 8, 2026. The transactions include a $1.5M unsecured convertible debenture, a $4.0M non-brokered unit financing, and settlements converting $12,700,631 of debt into units.
Certain financings involved insiders and a major vendor and relied on exemptions from formal valuation and minority approval because values did not exceed 25% of market capitalization. Securities issued are subject to statutory hold periods.
Sernova (OTC: SEOVF) reported results from its April 8, 2026 Annual General Meeting. Shareholders voted 93,246,234 common shares (27.31% of outstanding) and reelected all directors.
Resolutions passed include appointing Ernst & Young as auditor; issuing 65,831,880 units to Evotec to settle $12,508,057.25 of debt; issuing units to management to settle $192,574.26; and a private placement of 26,666,667 units to an insider for $4.0 million net proceeds.
Sernova (OTC: SEOVF) closed a non-brokered private placement on March 24, 2026, raising $2.1 million by issuing 13,762,659 units at $0.15 per unit. Each unit includes one common share and one warrant exercisable at $0.25 for 36 months, subject to acceleration.
The financing, together with a $5.5 million commitment from a board member and the expected near-term retirement of approximately $17 million of debt, is intended to strengthen the balance sheet and advance the Cell Pouch Bio-hybrid Organ clinical program for type 1 diabetes.
Sernova (OTC: SEOVF) announced financing transactions totaling $7.1 million on March 4, 2026, including three private financings: $1.6M non‑brokered equity, $1.5M convertible debenture, and $4.0M insider equity subject to shareholder approval.
Proceeds will retire a $4.0M secured term loan if approved and collectively materially improve the company's capital structure and liquidity ahead of an AGM on April 8, 2026.
Sernova (OTC: SEOVF) announced proposed amendments to outstanding warrants, subject to TSX approval, effective March 6, 2026.
The company will extend 19,977,050 non‑insider warrants (originally expiring March 3, 2026) to March 3, 2027, and will amend terms of 5,571,250 October–November 2025 warrants and finders warrants by reducing the exercise price to $0.25 and adding an acceleration clause tied to a 5‑day VWAP > $0.50. Insiders' warrants will not be amended.
Sernova Biotherapeutics (OTCQB: SEOVF), a regenerative medicine company developing Cell Pouch Bio-hybrid Organ for type 1 diabetes, has announced a significant CAD $13.3 million debt-to-equity conversion of outstanding accounts payable.
The conversion was executed through a non-brokered private placement of 66.3 million units at $0.19 per unit. Each unit includes one share (common or preferred) and two half warrants exercisable at $0.25 and $0.30 for 2 and 3 years, respectively. Additionally, the company successfully negotiated to defer its $4 million term debt repayment until April 2026.
The company's management, including CEO and CFO, participated in the conversion, demonstrating internal confidence in Sernova's direction toward advancing its phase 1/2 clinical trial for type 1 diabetes treatment.
Sernova Biotherapeutics (OTCQB:SEOVF) has announced a significant collaboration with Eledon Pharmaceuticals to advance their Type 1 Diabetes (T1D) treatment program. The partnership will evaluate Eledon's immunosuppressive agent tegoprubart in Cohort C of Sernova's Phase 1/2 clinical trial of its Cell Pouch Bio-hybrid Organ.
The collaboration aims to replace tacrolimus with tegoprubart, as previous studies showed promising results where T1D patients achieved normal blood sugar levels and insulin independence. Notably, islet engraftment was 3-5 times higher with tegoprubart compared to tacrolimus-based immunosuppression, with better graft survival and function.
The partnership combines Sernova's retrievable Bio-hybrid Organ technology with Evotec's stem cell-derived islet-like clusters and Eledon's innovative immunosuppression approach, positioning it as a potential leading solution for a functional T1D cure.
Sernova Biotherapeutics (SEOVF), a regenerative medicine company developing Cell Pouch Bio-hybrid Organ for type 1 diabetes treatment, announced the resignation of its Board Chair, Ross Haghighat. The resignation was tendered on May 24th, 2025, and accepted by Sernova's Board of Directors. The company expressed gratitude for Haghighat's leadership and extended well wishes for his future endeavors.